DelveInsight’s, “Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Overview
MAPK forms the backbone of four primary signal transduction cascades leading to the phosphorylation and activation of extracellular signal-regulated kinases 1 and 2 (ERK1--2), JNK, p38 and ERK5. MAPK kinases 1 and 2, commonly known at MEK1--2, are referred to as MEK. Because of their importance in cell proliferation and signaling, MAPK pathways are being targeted for new drugs for oncology, inflammation and other conditions. Several inhibitors of MEK1--2 (MAPK kinases 1 and 2) are nearing, or are currently in, clinical trials for oncology.
MEK1 and 2 are downstream of genes frequently mutated in tumors (such as EGFR, RAS and RAF), and in preclinical models, MEK inhibitors have demonstrated potent antitumor activity. MEK inhibitors have shown objective responses when used as monotherapy, particularly in tumors with known BRAF-activating mutations.
The companies and academics are working to assess challenges and seek opportunities that could influence Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors R&D. The therapies under development are focused on novel approaches for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors.
This segment of the Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Emerging Drugs
Selumetinib - AstraZeneca
Koselugo (selumetinib) is inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Both MEK and ERK are critical components of the RAS-regulated RAF-MEK-ERK pathway, which is often activated in different types of cancers.
Koselugo was granted US FDA Breakthrough Therapy Designation in April 2019, Rare Pediatric Disease Designation in December 2019, Orphan Drug Designation in February 2018, EU orphan designation in August 2018 and Swissmedic Orphan Drug Status in December 2018 for the treatment of paediatric patients with NF1 PN.
Further product details are provided in the report……..
This segment of the report provides insights about the different Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors. The companies which have their Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Astrazeneca.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors - DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Collaboration Deals
Late Stage Products (Phase III)
Selumetinib- AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Trametinib - Novartis
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CS 3006: CStone Pharmaceuticals
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
FCN 159: Chongqing Fochon Pharmaceutical
Drug profiles in the detailed report…..
Inactive Products
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Companies
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Products
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Unmet Needs
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Market Drivers and Barriers
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors- Future Perspectives and Conclusion
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Analyst Views
Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2)Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2)Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• AstraZeneca
• CStone Pharmaceuticals
• AUM Biosciences
• Novartis
• Array BioPharma
• Chongqing Fochon Pharmaceutical
